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Abstract
Background: Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and
is inhibited by sarilumab, a human monoclonal antibody blocking the IL-6 receptor alpha (IL-6Rα). The effects of
sarilumab plus methotrexate (MTX) on serum biomarkers of joint damage and bone resorption were assessed in
two independent studies (phase II (part A) and phase III (part B)) of patients with RA with a history of inadequate
response to MTX from the MOBILITY study (NCT01061736).
Methods: Serum samples were analyzed at baseline and prespecified posttreatment time points. Biomarkers of
tissue destruction, cartilage degradation, and synovial inflammation were measured in part A; assessment of these
markers was repeated in part B and included additional analysis of biomarkers of bone formation and resorption
(including soluble receptor activator of nuclear factor-kB ligand (sRANKL)). A mixed model for repeated measures
was used to compare treatment effects on change in biomarkers. Additionally, changes from baseline in biomarkers
were compared between American College of Rheumatology 50 % responders and nonresponders and between
patients who achieved or did not achieve low disease activity (LDA), separately by treatment group, at week 24.
Results: In part A, sarilumab 150 and 200 mg every 2 weeks (q2w) significantly reduced biomarkers of tissue
destruction, cartilage degradation, and synovial inflammation at both 2 and 12 weeks posttreatment (p < 0.05 vs
placebo). These results were replicated in part B, with markers of these damaging processes reduced at weeks 2
and 24 (p < 0.05 vs placebo). Additionally, sarilumab 200 mg q2w significantly reduced both sRANKL and sRANKL/
osteoprotegerin ratio at week 24 (p < 0.01 vs placebo). Trends for reduction were noted for several biomarkers in
patients who achieved LDA compared with those who did not.
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Conclusions: Sarilumab plus MTX significantly suppressed biomarkers of bone resorption and joint damage, as
compared with placebo plus MTX, in patients with RA. Additional work is needed to determine whether differences
in biomarker profiles at baseline or posttreatment can identify patients who achieve improvement in disease
activity.
Trial registration: ClinicalTrials.gov, NCT01061736, February 2, 2010.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease char-
acterized by chronic overactivation of the inflammatory
system and progressive joint destruction [1]. The localized
joint symptoms observed in RA result from persistent
synovial inflammation associated with damage to articular
cartilage and underlying bone [1, 2], which may lead to
progressively impaired function and disability [3].
Both innate and adaptive immune processes mediated
by cytokine activity play a role in the pathophysiology of
RA [4]. For example, the concentration of interleukin 6
(IL-6) is increased in the serum and synovial fluid of
patients with RA relative to healthy individuals [5] and
correlates with disease activity and joint destruction [4].
Elevation of IL-6 concentrations in joints may facilitate
synovial fibroblast activation, and bone resorption and
joint damage, through osteoclast formation [6, 7]. The
combination of reduced bone formation and increased
bone resorption is a characteristic feature of RA [8].
Studies in cell cultures and mouse models have demon-
strated the critical role of IL-6 in the induction of bone-
resorptive factors (e.g., receptor activator of nuclear
factor-kB ligand (RANKL)) and joint-destructive proteins
(e.g., matrix metalloproteinases (MMPs)) from osteoclasts
and fibroblast-like synoviocytes (FLS) [6, 9–12]. RANKL,
which exists in membrane-bound and soluble forms
(sRANKL), binds to RANK to induce osteoclast forma-
tion, survival, fusion, and activation [13]. Blockade of the
IL-6 receptor (IL-6R) inhibits osteoclast formation in vitro
and in vivo [14], and the induction of RANKL observed in
a collagen-induced arthritis monkey model is suppressed
by treatment with the IL-6R antibody tocilizumab [15].
IL-6R inhibition also blunts RANKL production in
FLS from patients with RA [9]. Osteoprotegerin (OPG),
a decoy receptor for RANKL, binds both forms of
RANKL, preventing activation of RANK and inhibiting
osteoclastogenesis [13]. The RANKL/OPG ratio regu-
lates the balance between bone turnover and bone for-
mation, with a higher ratio favoring enhanced bone
resorption [13, 16]. The formation of type I collagen frag-
ments, such as carboxy-terminal collagen crosslinks 1
(CTX-1), another indicator of bone turnover, is elevated
in patients with RA with joint destruction and radio-
graphic progression compared with controls [8, 17]. IL-6
signaling may also influence levels of serum osteocalcin
(OC), a marker of bone formation, further suggesting that
modulation of this pathway may positively impact the bal-
ance of bone turnover and formation [18].
Articular inflammation also leads to the secretion of
joint-destructive enzymes, (e.g., MMPs) by rheumatoid
synovial fibroblasts [19]; thus, MMP substrates can be
used as biomarkers of articular damage [18]. MMP-
cleaved fragments derived from collagens or the acute-
phase reactant C-reactive protein (CRP) have been
described in patients with established RA [18]. Collagen
types I, II, and III are the major components of bone,
cartilage, and synovium, respectively [20], and MMP-
cleaved fragments (C1M, C2M, and C3M, respectively)
may reflect articular remodeling [20, 21]. An MMP-
cleaved fragment of CRP, CRPM, is also a measure of
synovial inflammation [18, 22, 23].
Sarilumab is a human monoclonal antibody directed
against both membrane-bound and soluble forms of
IL-6Rα [24]. Sarilumab blockade of IL-6 binding to IL-
6Rα results in inhibition of IL-6–mediated signal
transduction [25]. The efficacy and safety of sarilumab
in combination with methotrexate (MTX) in patients
with moderate-to-severe RA and inadequate response
to MTX (MTX-IR) were evaluated in the two-part
(phase II (part A) and phase III (part B)) MOBILITY
trial (NCT01061736) [24, 26]. In MOBILITY A and B,
patients treated with sarilumab demonstrated statisti-
cally significant improvements in American College of
Rheumatology 20 % (ACR20) response rate at weeks
12 and 24, respectively. In MOBILITY B, patients
treated with sarilumab also demonstrated significant
improvements in least squares mean change in the
Health Assessment Questionnaire–Disability Index
(HAQ-DI) at week 16 and mean change in the van der
Heijde modified total Sharp score (mTSS) at week 52,
relative to placebo +MTX. The erosion score (ES) and
joint space narrowing (JSN), components of the mTSS,
were significantly reduced compared with placebo +
MTX as early as week 24. Sarilumab also reduced
serum levels of CRP, a marker of inflammation com-
monly assessed in patients with RA. Both doses of sari-
lumab were generally well-tolerated, and the most
common treatment-emergent adverse events included
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infections, neutropenia, injection site reactions, and in-
creased transaminases.
To better understand the mechanism through which
sarilumab inhibits progression of structural damage
(JSN and ES), we assessed biomarkers indicative of
joint damage and bone resorption. First, biomarkers
of bone and tissue destruction and synovial inflamma-
tion were measured in patients from the dose-ranging
MOBILITY part A study. These analyses were then
replicated and expanded upon (by including bio-
markers of bone formation and resorption) in patients
from the MOBILITY part B study.
Methods
Study design
The results of MOBILITY (NCT01061736), a two-part
(phase II (part A) and phase III (part B)), randomized,
double-blind, placebo-controlled, multicenter study that
evaluated the efficacy and safety of subcutaneous sarilu-
mab in combination with MTX in patients with active RA
and MTX-IR have previously been described [24, 26]. Part
A of MOBILITY was a 12-week, phase II, dose-ranging
study in patients with active RA who were randomized to
receive MTX in combination with placebo or one of five
subcutaneous sarilumab doses [26]. Patients who partici-
pated in part A were not eligible for part B, a 52-week,
phase III study evaluating the safety and efficacy of sarilu-
mab 150 mg and 200 mg every 2 weeks (q2w) in combin-
ation with MTX [24].
The protocol was approved by the appropriate ethics com-
mittees/institutional review boards (see “Acknowledgments”
for details), and all patients provided written informed
consent before study entry. The study was conducted in
compliance with institutional review board regulations,
the International Conference on Harmonisation Guide-
lines for Good Clinical Practice, and the Declaration of
Helsinki.
Sera collection
In part A, biomarkers were measured retrospectively in
sera collected at baseline (i.e., before receiving the first
treatment dose), and at 2 and 12 weeks posttreatment,
from patients receiving placebo +MTX (n = 45), sarilu-
mab 150 mg q2w +MTX (n = 46), or sarilumab 200 mg
q2w +MTX (n = 45). These doses were chosen for the
present analyses as they were selected for additional effi-
cacy and safety analyses in MOBILITY part B. Sera were
collected under fasting conditions at baseline and week
12 and under nonfasting conditions at week 2. Patients
were included in the analyses if at least one baseline
value and at least one postbaseline value were available
for one or more biomarkers under evaluation.
Biomarker analyses from part A were replicated and
expanded upon in part B in sera collected under fasting
conditions at baseline and 2, 24, and 52 weeks post-
treatment from randomly selected patients receiving
placebo +MTX (n = 128) or sarilumab 200 mg q2w +
MTX (n = 131). Sarilumab 200 mg q2w was chosen for
these analyses because this dose demonstrated better
efficacy compared with sarilumab 150 mg q2w with re-
spect to the bone and joint x-ray outcomes (i.e., mTSS,
ES, and JSN) in MOBILITY part B, and the additional
biomarkers measured reflect pathological processes as-
sociated with these scores. To be selected for this retro-
spective biomarker analysis, patients were required to
have baseline, week 2, and week 24 biomarker samples
and week 24 radiographic data available. Patients were
included in the analyses if the baseline value and at
least one postbaseline value were available for at least
1one biomarker under evaluation.
Starting at week 16 in MOBILITY part B, patients with
a lack of efficacy could be “rescued” by switching to
open-label sarilumab 200 mg q2w +MTX. Patients who
were rescued continued in the study according to their
planned visit schedule. Samples drawn from patients in
the placebo +MTX group before rescue medication were
included in the biomarker analysis. Serum samples ob-
tained from patients in the placebo +MTX group after
rescue medication were excluded from the analysis.
Biochemical marker assays
Retrospective analysis of serum concentrations of C1M,
C2M, C3M, and CRPM from patients from MOBILITY
part A were measured at Synarc (BioClinica Laboratory,
Lyon, France) using a validated proprietary enzyme-
linked immunosorbent assay (ELISA) by Nordic Bio-
science (Herlev, Denmark). The intra-assay and inter-assay
variation (coefficients of variation (CVs)) were <13.8 % for
C1M, <19.8 % for C2M, <16.4 % for C3M, and <14.2 % for
CRPM. Serum concentrations of C1M, C2M, C3M, MMP-
3, CTX-1, and OC from patients from MOBILITY part B
were measured at Nordic Bioscience using a validated
ELISA (Nordic Bioscience; all CVs <15 %). Serum MMP-3
(Quantikine total MMP-3 (R&D Systems, Minneapolis,
MN, USA); CV <10 %) and serum CTX-1 (CV <3.4 %)
were measured using the β-CrossLaps (Roche, Basel,
Switzerland) assay. Osteocalcin was measured using the
validated N-MID-OC kit (Roche; CV <4.6 %). Serum
concentrations of sRANKL (human sRANKL ELISA (Bio-
Vendor, Brno, Czech Republic)) and OPG (human OPG
ELISA (BioVendor)) were measured using validated assays
at Pacific Biomarkers (Seattle, WA, USA).
Statistical analysis
Patient baseline demographics and disease parameters
are presented as mean (± standard deviation). Given the
non-normal distribution of several biomarkers, median
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serum concentrations (quartile 1 to quartile 3 interval)
were reported for baseline measures.
To evaluate differences in pharmacodynamic changes
between sarilumab +MTX and placebo +MTX, a mixed-
effect model with repeated measures (MMRM) was
performed on rank-transformed percent change from
baseline (analysis of variance (ANOVA)-type method),
with the treatment, visit, and treatment-by-visit inter-
action included as fixed effects. Given the similar base-
line biomarker values in each treatment group, baseline
biomarker values were not included in the model. An
MMRM was also performed on the log-transformed
sRANKL/OPG ratio (to yield a normal distribution)
with treatment, visit, and treatment-by-visit interaction
as fixed effects, and baseline biomarker value and baseline
biomarker-value-by-visit interaction as fixed covariates.
An unstructured covariance structure was assumed in all
models. The Bonferroni correction was used to adjust
P values for multiplicity. A P value <0.05 after adjust-
ment was considered significant.
For exploratory purposes, percent changes from baseline
in biomarkers and sRANKL/OPG were also compared
between responders and nonresponders (patients who
achieved or did not achieve ACR50 or low disease activity
(LDA), as measured by 28-joint disease activity score by
CRP (DAS28-CRP) <3.2) at week 24 using similar
methods and after adjustment for baseline values, separ-
ately by treatment group; nominal P values are reported.
Analyses were performed using SAS® v9.2 or higher (SAS
Institute, Cary, NC, USA).
Results
Patient demographics, disease parameters, and baseline
biomarker serum concentrations
Baseline disease characteristics in the biomarker ana-
lyses were similar to those in the overall study [24, 26].
In part A (Table 1), the mean age of patients across all
treatment groups in these biomarker analyses was 51.0
± 13.1 years, and patients had a mean RA duration of
7.2 ± 7.3 years. Patients across all treatment groups dis-
played similar baseline disease characteristics, including
tender joint count (27.7 ± 16.2), swollen joint count
(17.7 ± 10.8), and CRP concentration (3.0 ± 3.4 mg/dL).
In part B (Table 2), the mean age of patients across all
treatment groups in these biomarker analyses was 50.2
± 11.5 years, and patients had a mean RA duration of
8.6 ± 7.5 years. Patients across all treatment groups dis-
played similar baseline disease characteristics, including
tender joint count (26.6 ± 14.7), swollen joint count
(16.2 ± 9.4), CRP concentration (1.9 ± 2.0 mg/dL), and
mTSS (48.8 ± 66.3). Median baseline serum concentra-
tions of all assayed biomarkers were generally compar-
able across treatment groups in part A (Table 1) and
part B (Table 2).
Biomarkers of joint inflammation and damage
Serum concentrations of MMP-generated biomarkers re-
lated to joint damage and tissue turnover were measured
first in part A (baseline, week 2, and week 12) and
subsequently in part B (baseline, week 2, and week 24).
In part A, the decrease in serum concentration of these




Sarilumab 150 mg q2w +MTX
(n = 46)
Sarilumab 200 mg q2w +MTX
(n = 45)
Totala (n = 136)
Baseline demographic and disease parameters
Age, mean ± SD, years 54.7 ± 13.1 49.8 ± 12.7 48.4 ± 12.8 51.0 ± 13.1
Sex, female, % 75.6 84.8 80.0 80.1
Duration of RA, mean ± SD, years 8.0 ± 8.6 7.1 ± 6.7 6.4 ± 6.4 7.2 ± 7.3
Anti-CCP antibody positive, %b 73.7 95.0 90.0 86.4
Rheumatoid factor positive, % 66.7 87.0 88.9 80.9
Tender joint count, mean ± SD 27.9 ± 17.0 28.1 ± 17.2 26.9 ± 14.6 27.7 ± 16.2
Swollen joint count, mean ± SD 17.6 ± 12.3 18.3 ± 10.9 17.2 ± 9.3 17.7 ± 10.8
CRP, mean ± SD, mg/dL 2.8 ± 2.8 2.6 ± 2.8 3.4 ± 4.4 3.0 ± 3.4
Baseline biomarker serum concentrations, median (quartile 1/quartile 3)
C1M, ng/mL 198.1 (132.0/263.4) 179.6 (140.2/235.8) 172.3 (132.4/273.0) 179.6 (133.5/259.3)
C2M, ng/mL 0.2 (0.2/0.3) 0.3 (0.2/0.3) 0.2 (0.2/0.4) 0.2 (0.2/0.3)
C3M, ng/mL 45.6 (38.9/58.1) 47.6 (38.3/60.2) 47.9 (37.9/59.3) 47.5 (38.3/59.0)
CRPM, ng/mL 17.3 (12.1/21.7) 16.5 (14.1/21.4) 16.3 (13.9/22.3) 16.7 (13.1/21.7)
aAll patients receiving placebo, sarilumab 150 mg q2w, or sarilumab 200 mg q2w. bResults not available for the entire biomarker population. C1M collagen type I
MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, C3M collagen type III MMP-cleaved fragment, CCP cyclic citrullinated peptide, CRPM C-
reactive protein MMP-derived fragment, MMP matrix metalloproteinase, MTX methotrexate, q2w every 2 weeks, RA rheumatoid arthritis, SD standard deviation
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biomarkers from baseline was significantly greater after
treatment with sarilumab 150 and 200 mg q2w com-
pared with placebo; suppression was numerically greater
with the 200 mg q2w dose compared with the 150 mg
q2w dose. The greatest change observed was in C1M,
which was significantly suppressed in patients receiving
sarilumab relative to patients receiving placebo. Dose-
dependent decreases in C1M were observed with sarilu-
mab treatment at week 2 (Fig. 1a); serum concentration
of C1M was further suppressed at week 12 in the sarilu-
mab 150 mg q2w group to levels observed in the
200 mg q2w group. A 33.6 % reduction from baseline
was observed in the sarilumab 150 mg q2w group at
week 2, with a 52.5 % reduction from baseline observed
at week 12 (p < 0.0001 vs placebo for both time points).
In the sarilumab 200 mg q2w group, a 59.4 % reduction
from baseline at week 2 and a 61.4 % reduction from
baseline at week 12 was observed (p < 0.0001 vs placebo
at both time points). Treatment with placebo resulted in
a 4.1 % decrease from baseline over a 12-week period. In
part B, circulating C1M was reduced by 50.1 % at week
2 and 60.3 % at week 24 with sarilumab 200 mg q2w
compared with a 2.3 % increase and an 8.1 % reduction
from baseline with placebo (p < 0.0001 at both time
points; Fig. 1b).
Modest changes in the cartilage degradation marker
C2M were observed in part A. There was a 0.9 %
increase from baseline over the 12 weeks in the placebo
group, while sarilumab reduced C2M by >10.0 % by
week 2 (sarilumab 150 mg q2w, p < 0.05 vs placebo; sari-
lumab 200 mg q2w, p < 0.001 vs placebo; Fig. 1c). This
decrease was maintained by sarilumab 150 mg q2w at
week 12 (10.2 % decrease from baseline; p < 0.05 vs
placebo); C2M was further suppressed by sarilumab
200 mg q2w at this time point (18.2 % decrease from
baseline; p < 0.001 vs placebo). Sarilumab suppression of
C2M was less pronounced, and the difference relative to
placebo was not observed in part B (Fig. 1d).
In part A, sarilumab 150 mg q2w decreased the syn-
ovial inflammation marker C3M by 18.9 % (p < 0.001 vs
placebo) and 26.6 % (p < 0.0001 vs placebo) at weeks 2
and 12, respectively; reductions of 24.6 % (week 2) and
34.9 % (week 12) were observed in the sarilumab
200 mg q2w (p < 0.0001 vs placebo at both time points;
Fig. 1e). Similar results were observed in part B, in
which C3M was reduced by 23.8 % at week 2 and 31.5 %








Baseline demographic and disease parameters
Age, mean ± SD, years 51.1 ± 10.6 49.3 ± 12.3 50.2 ± 11.5
Sex, female, % 77.3 84.7 81.1
Duration of RA, mean ± SD, years 9.1 ± 8.2 8.1 ± 6.7 8.6 ± 7.5
Anti-CCP antibody positive, % 82.8 87.0 84.9
Rheumatoid factor positive, % 87.5 87.8 87.6
Tender joint count, mean ± SD 27.3 ± 14.8 25.9 ± 14.5 26.6 ± 14.7
Swollen joint count, mean ± SD 15.8 ± 8.0 16.6 ± 10.6 16.2 ± 9.4
CRP, mean ± SD, mg/dL 1.7 ± 1.9 2.1 ± 2.1 1.9 ± 2.0
mTSS, mean ± SD 51.8 ± 72.1 45.9 ± 60.2 48.8 ± 66.3
Baseline biomarker serum concentrations, median (quartile 1/quartile 3)
C1M, ng/mL 114.0 (77.0/175.7) 120.5 (86.1/196.3) 119.6 (80.7/184.2)
C2M, ng/mL 0.3 (0.2/0.4) 0.3 (0.2/0.4) 0.3 (0.2/0.4)
C3M, ng/mL 43.1 (34.6/58.0) 45.4 (34.4/60.5) 44.2 (34.5/59.9)
CTX-1, ng/mL 0.4 (0.3/0.6) 0.4 (0.3/0.5) 0.4 (0.3/0.5)
MMP-3, ng/mL 41.9 (24.6/77.6) 38.9 (21.3/68.7) 40.3 (22.3/73.1)
OC, ng/mL 18.3 (13.0/25.0) 18.6 (14.6/24.7) 18.5 (13.5/24.7)
OPG, pmol/L 4.9 (3.9/6.3) 5.4 (3.9/6.7) 5.2 (3.9/6.5)
sRANKL, pmol/L 1012.5 (385.0/3893.0) 1096.0 (393.0/2161.5) 1026.0 (387.0/2748.5)
sRANKL/OPG 245.1 (64.4/836.5) 186.3 (71.8/401.2) 212.6 (70.8/509.7)
aAll patients receiving placebo or sarilumab 200 mg q2w. C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, C3M collagen
type III MMP-cleaved fragment, CCP cyclic citrullinated peptide, CRP C-reactive protein, CTX-1 carboxy-terminal collagen crosslinks 1, MMP matrix metalloproteinase,
mTSS van der Heijde modified total Sharp score, MTX methotrexate, OC osteocalcin, OPG osteoprotegerin, q2w every 2 weeks, RA rheumatoid arthritis, SD standard
deviation, sRANKL soluble receptor activator of nuclear factor-kB ligand
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at week 24 (p < 0.0001 vs placebo at both time points;
Fig. 1f ), compared with a 5.3 % reduction over 24 weeks
observed with placebo.
Although placebo had minimal effects on CRPM, a
marker of synovial inflammation, sarilumab reduced
CRPM serum concentrations relative to baseline at weeks
2 and 12 in part A (Fig. 1g). Maximum suppression was
observed at week 12 in both sarilumab groups (150 mg
q2w, −25.0 % from baseline; 200 mg q2w, −35.8 % from
baseline; p < 0.0001 vs placebo for both sarilumab groups).
In part B, significantly lower serum concentrations of
MMP-3, another marker of synovial inflammation, were
observed at week 2 with sarilumab 200 mg q2w compared
with placebo (−5.4 % from baseline vs −0.4 % from base-
line, respectively; p < 0.05), and these concentrations were
further decreased from baseline by week 24 (−44.2 % vs
−2.7 %, respectively; p < 0.0001; Fig. 1h).
Markers of bone resorption
Serum concentrations of biomarkers related to bone re-
sorption were measured in part B. Sarilumab 200 mg
q2w significantly reduced sRANKL relative to placebo at
week 2 (p < 0.05; Fig. 2a), and sRANKL continued to
decrease through week 24 in both groups, with greater
suppression observed with sarilumab compared with





























































































































































































































Placebo + MTX Sarilumab 150 mg q2w + MTX Sarilumab 200 mg q2w + MTX
Fig. 1 Sarilumab decreases markers of joint damage and inflammation in MOBILITY parts A and B (a and b, C1M; c and d, C2M; e and f, C3M; g,
CRPM; and h, MMP-3). *p < 0.05 vs placebo. **p < 0.01 vs placebo. ***p < 0.0001 vs placebo. C1M collagen type I MMP-cleaved fragment, C2M col-
lagen type II MMP-cleaved fragment, C3M collagen type III MMP-cleaved fragment, CRPM C-reactive protein MMP-derived fragment, MMP-3 matrix
metalloproteinase 3, MTX methotrexate, NS not significant, (Q1,Q3) quartile 1 to quartile 3 interval, q2w every 2 weeks
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suppressed sRANKL more than placebo (−28.6 % vs
−10.2 % from baseline, respectively; p < 0.01). No signifi-
cant differences from baseline in OPG were observed in
either treatment group at the time points measured
(Fig. 2b). However, because of the suppressive effect of
sarilumab on sRANKL, a significant decrease in the
sRANKL/OPG ratio was observed in the sarilumab
200 mg q2w group compared with placebo (p < 0.01) at
week 24 (Fig. 2c).
Moderate reductions in CTX-1 were observed at week
24 in the sarilumab 200 mg q2w and placebo groups
(−6.7 % and −7.8 % from baseline, respectively) and
week 52 (−7.7 % and −7.0 %, respectively), but there
were no significant differences between treatment
groups at either time point examined (data not shown).
Marker of bone formation
Serum concentrations of OC were evaluated at baseline,
week 24, and week 52 in samples from part B. Serum
OC concentrations remained steady after treatment with
placebo over the 52-week study. A numeric trend toward
a larger increase in OC was observed with sarilumab
200 mg q2w at week 24 (10.9 %; p = 0.107) and at week
52 (13.2 %; p = 0.057, unadjusted p = 0.029) vs placebo
(2.1 % and 0.1 %, respectively), although these results
were not significant after adjustment for multiplicity
(Fig. 3).
Biomarker changes by ACR50 response at week 24
Percent change in serum concentrations of biomarkers
were examined in ACR50 responders (placebo, n = 34
(26.6 %); sarilumab 200 mg q2w, n = 67 (51.1 %)) and
nonresponders (placebo, n = 94 (73.4 %); sarilumab
200 mg q2w, n = 64 (48.9 %)) at week 24 in part B
(Table 3). C-reactive protein (a marker of inflamma-
tion) and markers of bone resorption and joint damage
were assessed. Placebo-treated ACR50 responders dem-
onstrated a greater reduction in CRP from baseline
compared with ACR50 nonresponders, although this ef-
fect was not observed until week 8 (−30.6 % vs −8.2 %;
nominal p < 0.05). Only a small difference in the magni-
tude of CRP suppression was observed between sarilu-
mab responders and nonresponders at this time point
(−96.6 % vs −93.3 %; nominal p < 0.05).
ACR50 responders receiving placebo demonstrated
greater reductions in C1M, sRANKL, and the log
sRANKL/OPG ratio at week 24 compared with placebo-
treated patients who did not achieve ACR50. Other bio-
markers suppressed by sarilumab treatment (e.g., C3M)
did not significantly differ by ACR50 response.
Biomarker changes by LDA status at week 24
Serum concentrations of biomarkers were also examined
in patients who achieved LDA (placebo, n = 37 (28.9 %);
sarilumab 200 mg q2w, n = 72 (55.0 %)) and those who
did not achieve LDA (placebo, n = 91 (71.1 %); sarilumab













































































Fig. 2 Sarilumab decreases sRANKL, and log RANKL/OPG ratio, markers of bone resorption in MOBILITY part B (a, sRANKL; b, OPG; c, log sRANKL/
OPG ratio). *p < 0.05 vs placebo. **p < 0.01 vs placebo. MTX methotrexate, NS not significant, OPG osteoprotegerin, (Q1,Q3) quartile 1 to quartile 3



























Fig. 3 Sarilumab increases OC, a marker of bone formation (nominal
p = 0.057 vs placebo, week 52). MTX methotrexate, OC osteocalcin,
(Q1,Q3) quartile 1 to quartile 3 interval, q2w every 2 weeks
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200 mg q2w, n = 59 (45.0 %)) at week 24 in part B
(Table 4). Suppression of CRP according to LDA status
was similar to that observed according to ACR50
response. Placebo-treated patients who achieved LDA
demonstrated a greater reduction in CRP compared with
patients who did not achieve LDA at week 24 (−31.9 %
vs −4.2 %; nominal p < 0.01) only. As with the ACR50
response analysis, the magnitude of CRP suppression
observed in patients who achieved or did not achieve
LDA after sarilumab treatment was only slightly different
(−96.9 % vs −90.2 %; nominal p < 0.01).
Trends for reductions in MMP-3, OPG, and sRANKL
were observed in both treatment groups between patients
who achieved LDA compared with patients who did not.
Most of the differences were not significant with the excep-
tion of C1M, which was reduced in placebo-treated and
sarilumab-treated patients. C3M reduction was not differ-
ent between patients who did or did not achieve LDA, des-
pite suppression by sarilumab treatment (data not shown).
Discussion
The effects of treatment with sarilumab plus MTX on
biomarkers of joint and tissue destruction and bone
resorption were examined in MTX-IR patients with RA
from the MOBILITY trial. Given the reduction in the
progression of structural damage observed in patients
receiving sarilumab 150 or 200 mg q2w (particularly in
those receiving 200 mg q2w) [24], blockade of IL-6Rα
with this antibody was predicted to significantly impact
Table 3 Median percent change from baseline in biomarker
concentration in ACR50 responder and nonresponder patients
at week 24














Week 2 8.5 −3.3 −94.2 −87.5
Week 24 −40.3** −4.2 −96.3 −94.1
C1M
Week 2 1.6 2.6 −57.1* −43.8
Week 24 −26.7* −7.2 −62.8** −57.0
C2M
Week 2 0.0 3.4 −4.3 −4.3
Week 24 0.0 3.1 0.0 −6.5
MMP-3
Week 2 −5.1 1.9 −10.8* −4.4
Week 24 −6.3 −1.4 −50.9 −30.6
OPG
Week 2 1.7 0.0 −6.0 −2.2
Week 24 0.0 −1.8 −1.1 −2.0
sRANKL
Week 2 −5.4 −1.2 −7.9 −2.7
Week 24 −23.6* −0.8 −31.4 −24.9
Percent change from baseline in biomarkers transformed in rank was
compared between responder and nonresponder patients at week 24 using
an analysis of variance (ANOVA)-type method, with response, visit, and
response-by-visit interaction as fixed effects, rank-transformed baseline
biomarker value and rank-transformed baseline biomarker-value-by-visit
interaction as fixed covariates, and assuming an unstructured covariance
structure. The model was run separately by treatment group (sarilumab
200 mg q2w and placebo)
ACR American College of Rheumatology
C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-
cleaved fragment, CRP C-reactive protein, DAS28-CRP 28-joint disease activity
score by CRP, LDA low disease activity, MMP matrix metalloproteinase, MTX
methotrexate, OPG osteoprotegerin, q2w every 2 weeks, sRANKL soluble
receptor activator of nuclear factor-kB ligand. *Nominal p < 0.05 vs nonresponder.
**Nominal p < 0.01 vs nonresponder
Table 4 Median percent change from baseline in biomarker
concentration in patients who achieved or did not achieve LDA
(DAS28-CRP <3.2) at week 24














Week 2 1.2 −2.9 −95.0** −83.5
Week 24 −31.9** −4.2 −96.9** −90.2
C1M
Week 2 4.5 2.2 −55.8* −45.1
Week 24 −16.8* −4.3 −65.7** −54.1
C2M
Week 2 0 3.4 0* −14.3
Week 24 0 3.5 0 −6.7
MMP-3
Week 2 −2.0 2.3 −7.2 −3.3
Week 24 −9.7 0.4 −47.2 −34.2
OPG
Week 2 −5.1 1.6 −6.5* −0.9
Week 24 −1.9 −1.8 −4.6 0.9
sRANKL
Week 2 −4.7 −0.8 −7.9 −2.3
Week 24 −16.2* −0.8 −39.7 −25.8
Percent change from baseline in biomarkers transformed in rank was
compared between responder and nonresponder patients at week 24 using
an analysis of variance (ANOVA)-type method, with response, visit, and
response-by-visit interaction as fixed effects, rank-transformed baseline bio-
marker value and rank-transformed baseline biomarker-value-by-visit inter-
action as fixed covariates, and assuming an unstructured covariance structure.
The model was run separately by treatment group (sarilumab 200 mg q2w
and placebo).
C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-
cleaved fragment, CRP C-reactive protein, DAS28-CRP 28-joint disease activity
score by CRP, LDA low disease activity, MMP matrix metalloproteinase, MTX
methotrexate, OPG osteoprotegerin, q2w every 2 weeks, sRANKL soluble recep-
tor activator of nuclear factor-kB ligand. *Nominal p < 0.05 vs nonresponder.
**Nominal p < 0.01 vs nonresponder
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serum concentrations of biomarkers of joint and tissue
destruction and bone resorption. Consistent with this
prediction, sarilumab significantly reduced concentra-
tions of markers of joint inflammation (e.g., C3M and
MMP-3) and collagen degradation (C2M) compared
with placebo. A rapid reduction in several MMP-generated
biomarkers was observed as early as 2 weeks after initiation
of sarilumab, was sustained for at least 24 weeks, and was
dose dependent. Significant correlations between baseline
concentrations of C1M, a marker of soft tissue destruction,
have previously been observed with CRP concentrations
and structural damage in MTX-IR patients with RA, indi-
cating the potential prognostic utility of this marker [27].
Reductions in MMP-3 (stromelysin-1), a marker of syn-
ovial inflammation, were also observed at week 2, with
continuing reductions observed at week 24, in patients
treated with sarilumab compared with those treated with
placebo. MMP-3 is highly elevated in the joint tissue and
synovial fluid of patients with RA [19, 28], and higher
baseline concentrations of this enzyme are associated with
disease activity and radiographic progression, particularly
in individuals with early RA (i.e., duration of symptoms
<12 months) [19].
Serum concentrations of a separate marker of syn-
ovial inflammation, CRPM, were also reduced at weeks
2 and 12 in patients treated with sarilumab compared
with placebo. Maximum suppression was observed at
week 12 in the sarilumab 150 and 200 mg q2w groups,
although the mechanism underlying this reduction re-
mains uncertain. Previous reports from the MOBILITY
study have shown that sarilumab significantly decreases
CRP [24, 26]; as such, the reduction in CRPM observed
in the present study could be due to a decrease in pro-
teolysis and/or a decrease in substrate available for
MMP-mediated cleavage.
Sarilumab was also associated with a trend toward an
increase in OC, a marker of bone formation, in the MTX-
IR patient population. Together, the data in the present
report are consistent with other studies, in which blockade
of IL-6R with tocilizumab was associated with reduced cir-
culating serum concentrations of MMP-3 and MMP-3-
cleaved fragments, including C1M, C2M, C3M, and
CRPM, and augmentation of OC [18, 27, 29].
Importantly, this placebo-controlled study reported
that an inhibition of IL-6 signaling leads to significant
sRANKL reduction in patients with MTX-IR RA, which
may indicate a potential mechanism through which in-
hibition of IL-6 signaling prevents further progression
of bone resorption and loss in this patient population. Pre-
vious work has shown that RANKL concentration is nega-
tively correlated with bone mineral density (BMD) in
patients with RA [30, 31] and can be blocked by anti-
RANKL monoclonal antibodies that increase BMD, such as
denosumab [32]. Furthermore, in patients with refractory
RA who received anti-tumor necrosis factor (TNF) therapy,
sRANKL serum concentrations of RANKL have been sug-
gested as potential predictive markers of remission [33].
Sarilumab did not significantly affect serum concen-
trations of OPG, a decoy receptor for RANKL that
negatively regulates osteoclast maturation, compared
with placebo [34]. This is in contrast with previous ob-
servations, in which patients with RA who had received
treatment with tocilizumab demonstrated enhanced
bone marrow OPG expression relative to patients with
RA who had not received biologic therapy [35]. However,
in the present analysis of patients with moderate-to-severe
RA, blockade of IL-6Rα with sarilumab significantly de-
creased the sRANKL/OPG ratio, which is often used to
measure the magnitude of bone resorption [16] and has
been shown to predict 5-year and 11-year joint damage in
patients with early untreated RA [16, 36]. The current
data also support and expand upon previous work, in
which blockade of IL-6R with tocilizumab significantly im-
pacted bone resorption, particularly in patients achieving
remission or low disease activity [37].
Although sarilumab significantly suppressed one marker
of bone resorption, sRANKL, sarilumab did not signifi-
cantly modulate CTX-1 relative to placebo at either time
point examined. In a previous investigation, treatment
with tocilizumab had variable effects on serum concentra-
tions of CTX-1 [18]. In the present study, serum concen-
trations of CTX-1 were measured at baseline, week 24,
and week 52; as there may be a temporal relationship be-
tween IL-6Rα blockade and CTX-1 suppression, further
analysis at earlier time points may be warranted. CTX-1 is
created through cathepsin K cleavage of collagen type I
[20, 38]. The lack of CTX-1 modulation observed in the
present study suggests that sarilumab may not impact ca-
thepsin K cleavage of collagen type I and may only impact
MMP cleavage as reflected in reduction of C1M.
Although posttreatment differences were observed in
several biomarkers according to clinical response, most
of the significant differences relating to ACR50 response
were noted in the placebo group. Modest differences were
observed earlier in responders to sarilumab treatment.
Additional analysis is needed to determine if the baseline
biomarkers or changes in biomarkers can predict clinical
response to sarilumab.
The present investigation retrospectively evaluated
serum biomarker concentrations collected as part of two
independent, randomized, placebo-controlled trials, in
which patients with RA received placebo or sarilumab
with concomitant MTX. This design not only permitted
direct comparison between treatment groups but also
allowed for analysis of duration of biomarker responses.
This study design also provided a unique opportunity to
replicate biomarker assessments in two independent
cohorts of similar populations of MTX-IR patients with
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moderate-to-severe, active RA. The reductions observed
in markers of tissue destruction (C1M), cartilage de-
struction (C2M), and synovial inflammation (C3M) in
part A were also observed in part B. Evaluation of joint
damage progression in MOBILITY part B provided the
basis to also assess biomarkers of bone resorption (CTX-
1, OPG, sRANKL, and sRANKL/OPG ratio) and forma-
tion (OC). Future analysis will involve correlation of
these markers with the radiographic efficacy endpoints
(i.e., mTSS, ES, JSN) measured in the main study.
Despite these advantages, there are several limitations.
First, only circulating markers of joint damage and resorp-
tion were examined. Future studies are needed to examine
the effect of sarilumab levels on these markers in the syn-
ovial fluid or in synovial tissue. Second, biomarkers were
evaluated at a limited number of time points after treat-
ment. Dose-dependent effects observed in MOBILITY
part A were not evaluated in MOBILITY part B, which
only evaluated the effects of the sarilumab 200 mg q2w
dose. Finally, the current analyses do not take into consid-
eration concomitant medications (e.g., corticosteroids
[24]) that may possibly influence expression of biomarkers
examined in the present study (e.g., RANKL [39]). There-
fore, further analyses are needed to clarify the effect on
these biomarkers of sarilumab vs concomitant medication
vs their combination.
These data are consistent with previous studies and pro-
vide additional evidence of reduction in markers of bone
resorption in response to sarilumab treatment. Overall,
the study findings support a model wherein IL-6 signaling
inhibition reduces osteoclast-driven structural damage
and reduces joint inflammation markers in patients with
established RA and MTX-IR.
Conclusions
The present investigation demonstrated the pharmacody-
namic effects of sarilumab plus MTX on serum concen-
trations of biomarkers associated with joint and tissue
destruction and damage compared with placebo plus
MTX. In the future, quantitative measurements of bio-
markers of bone and cartilage damage may be useful as
prognostic markers to identify patients most in need of
treatment. Additionally, such measurements may also
serve as predictive markers of positive responses to IL-6
inhibition, allowing interpretation of potential treatment
efficacy earlier than radiological-based measurements
[40]. To explore the potential role of biomarkers of joint
and tissue destruction and inflammation in therapeutic
targeting, additional studies are necessary to determine
whether serum concentrations of these biomarkers of
joint damage, bone resorption, and synovial inflammation
can serve as early identifiers of both severe disease and pa-
tients likely to respond to sarilumab.
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